

Supplemental Data Table S1. Characteristics of the patients according to the presence or absence of CMV infection after allogeneic HSCT

| | Total (N=25) | CMV infection during 1 yr post-allogeneic HSCT | | <i>P</i> |
|--|-----------------|--|---------------|----------|
| | | Presence (N=16) | Absence (N=9) | |
| Age in months (median, range) | 33 (4-226) | 32 (4-163) | 67 (4-226) | 0.977 |
| Sex | | | | 0.364 |
| Male | 19 | 11 | 8 | |
| Female | 6 | 5 | 1 | |
| Diagnosis | | | | 0.587 |
| Hematologic malignancy | 20 | 12 | 8 | |
| Primary immune deficiency | 2 | 1 | 1 | |
| Solid tumor | 3 | 3 | 0 | |
| Source of stem cell | | | | 0.364 |
| Peripheral blood & bone marrow | 19 | 11 | 8 | |
| Cord blood | 6 | 5 | 1 | |
| ABO match | | | | 0.864 |
| Match | 8 | 6 | 2 | |
| Major mismatch | 11 | 6 | 5 | |
| Minor mismatch | 6 | 4 | 2 | |
| HLA match | | | | 0.010 |
| Match | 8 | 2 | 6 | |
| Mismatch | 17 | 14 | 3 | |
| CMV serostatus of donor/recipient | | | | 0.215 |
| Positive/Positive | 16 | 11 | 5 | |
| Negative/Positive | 7 | 5 | 2 | |
| Negative/Negative | 2 | 0 | 2 | |
| Conditioning regimen | | | | 0.115 |
| Non-myeloablative & reduced | 14 | 11 | 3 | |
| Myeloablative | 11 | 5 | 6 | |
| QF-CMV at post-allogeneic HSCT 4 weeks | | | | 0.088 |
| Positive | 8 | 4 | 4 | |
| Negative | 7 | 3 | 4 | |
| Indeterminate | 10 | 9 | 1 | |
| N of CD34 ⁺ cells transplanted ($\times 10^6$ /kg) | | | | 0.401 |
| ≥ 5 | 9 | 7 | 2 | |
| < 5 | 16 | 9 | 7 | |
| N of death within 1 yr | 6 | 2 | 4 | |

Abbreviations: CMV, cytomegalovirus; HSCT, hematopoietic stem cell transplantation.